<DOC>
	<DOCNO>NCT00456027</DOCNO>
	<brief_summary>This study investigate safety 20ug Diamyd® ( rhGAD65 formulate Alhydrogel® ) , administer subcutaneously four week apart patient Latent Autoimmune Diabetes Adult ( LADA ) .</brief_summary>
	<brief_title>Safety Diamyd® Patients With LADA ( Latent Autoimmune Diabetes Adult )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Key Male female patient 3070 year age diagnose type 2 diabetes within 5 year Presence GAD65 antibodies Detectable Cpeptide level Patients require treatment diet and/or oral hypoglycaemic agent ( OHA ) Written informed Consent Key Treatment insulin Intolerance OHA Secondary diabetes mellitus History certain disease condition ( e.g . anaemia , epilepsy , head trauma , neurological disease , alcohol drug abuse , HIV , hepatitis ) Treatment vaccine within one month prior first Diamyd® dose plan treatment vaccine 2 month second Diamyd® dose Participation clinical trial new chemical entity within previous 3 month Pregnancy ( plan pregnancy within one year 2nd administration ) Presence associate serious disease condition opinion investigator make patient noneligible study Significant illness diabetes within 2 week prior first dose Unwillingness comply provision protocol Clinically significant history acute reaction drug past Treatment immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>LADA</keyword>
	<keyword>Latent Autoimmune Diabetes Adult</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>HbA1c</keyword>
	<keyword>C-peptide</keyword>
</DOC>